Actelion Pharmaceuticals Ltd

Idorsia Pharmaceuticals Ltd

Sylvia Richard-Bildstein

Olivier Corminboeuf

Daniel Bur

Christoph Boss

Corinna Grisostomi

Hamed Aissaoui

Heinz Fretz

Thierry Sifferlen

Sylvaine Cren

Xavier Leroy

Davide Pozzi

Julien Pothier

Isabelle Lyothier

Thomas Weller

Romain Siegrist

Lubos Remen

Olivier Bezencon

Hervé Siendt

Walter Fischli

Martin Bolli

Michel Therien

Daniel Dube

Francis Hubler

Francois Lehembre

John Scheigetz

Eva Caroff

Emmanuel Meyer

Philippe Guerry

Laetitia Pouzol

Patrick Sieber

Lorenza Wyder Peters

Shuguang Yuan

Dwight MacDonald

Dan McKay

Julien Hazemann

Austin Chih-Yu Chen

Philippe Risch

Hans-Peter Weber

Jerome Gabillet

David Powell

Walter Fiśchli

Oliver Corminboeuf

Alexia Chavanton-arpel

Oliver Allemann

Andrew Croxford

Herv Siendt

The present invention relates to derivatives of formula (I) wherein (R), R, R, R, R, R, Rand Arare as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

N-substituted indole derivatives as PGE2 receptor modulators

The present invention relates to pyrimidine derivatives of formula (I) wherein (R), R, R, R, R, Rand Arare as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

Pyrimidine derivatives as PGE2 receptor modulators

The present invention relates to phenyl derivatives of formula (I)

Phenyl derivatives as PGE2 receptor modulators

The present invention relates to pyrimidine derivatives of formula (I) wherein (R), R, R, R, R, Rand Arare as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

Pyrimidine derivatives

The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R), R, R, R, R, R, Rand Arare as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

Benzofurane and benzothiophene derivatives as PGE2 receptor modulators

The present invention relates to piperidine derivatives of formula (I) wherein Ar, Ar, R, R, R, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

Piperidine CXCR7 receptor modulators

The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.

NADPH oxidase 4 inhibitors

The present invention relates to piperidine derivatives of formula (I) wherein Ar, Ar, R, R, Rand Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

Piperdine CXCR7 receptor modulators

The invention relates to hydroxylated aminotriazole derivatives of formula (I), wherein Q, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Hydroxylated aminotriazole derivatives as ALX receptor agonists

The present invention relates to phenyl-substituted heterocyclyl derivatives of the formula (I), wherein Z, n, m, R, R, R, R, R, R, Rand Rare as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin Dreceptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators

The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a catalyst, wherein the method includes the steps of: (i) reacting the excess monomer(s) with an initiator in a solvent, said initiator being selected from among an amine and an amino alcohol, given that the initiator has at least one primary or secondary amine function; (ii) adding a catalyst, said catalyst being a non-nucleophilic base and including at least one neutral sp2 nitrogen atom; and (iii) neutralizing the reaction mixture. Said novel method is particularly advantageous in that it can be easily monitored and enables better modulation of the polymers, and thus of the properties thereof, than the methods of the prior art. The invention also relates to novel polymers that are obtainable by means of said method.

Bridged Spiro[2.4]heptane ester derivatives

The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I), wherein Y, Z, R, R, Rand Rare as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin Dreceptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators

The present invention relates to 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives of the formula (I), wherein R, R, Rand Rare as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin Dreceptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators

Growing community of inventors

Allschwil, Switzerland

Sylvia Richard-Bildstein